ORTEXORTEX News
Live short interest, options flow, and signals — free on ORTEX.Sign up free →
Market Commentary

Bears Zero In: Short Sellers Target New Names

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 1 min read

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Short sellers made some sharp moves this week. Several mid-cap stocks saw short interest spike fast, while one pet retailer remains trapped in a squeeze.

The Week's Biggest Movers

REPL (Replimune Group) saw the sharpest jump among larger names. SI as a percentage of free float leapt to 43.3% from 32.4% just seven days ago — a 10.9 percentage point surge. The clinical-stage oncology firm has limited borrow availability at just 1.2x short interest, raising squeeze risk.

Prison operator CXW (CoreCivic) delivered a different kind of shock. SI rocketed from 2.3% to 10.3% in one week — a near fivefold jump. Bears appear newly concerned after a period of minimal short interest in the name.

Chewy: Bears Giving Ground

CHWY continues to show a slow short squeeze developing. SI sat above 115% of free float in late July. By August 12 it had fallen to 94.3%. That's still extreme — but the direction favours bulls.

Wolfspeed Stays in Bears' Sights

WOLF shows no relief. SI climbed again to 85.2% of free float. It's up from 81% a week ago. Cost to borrow sits near 3.9% APR. Analysts have a negative return potential on the stock.

Galectin: High Score, High Risk

GALT carries an ORTEX short score of 90.3 — one of the highest in the market. SI stands at 77.3% of float with 24 days to cover. That combination makes it a prime squeeze candidate if any catalyst emerges.

This note is for informational purposes only and is not financial advice.

Stocks in this article

How this article was generated

Generated
13 Aug 2026, 16:03
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilization

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.